263 related articles for article (PubMed ID: 15158473)
21. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.
Chu LH; Chan SH; Tsai SN; Wang Y; Cheng CH; Wong KB; Waye MM; Ngai SM
J Cell Biochem; 2008 Aug; 104(6):2335-47. PubMed ID: 18442051
[TBL] [Abstract][Full Text] [Related]
22. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.
Ni L; Zhu J; Zhang J; Yan M; Gao GF; Tien P
Biochem Biophys Res Commun; 2005 Apr; 330(1):39-45. PubMed ID: 15781229
[TBL] [Abstract][Full Text] [Related]
23. Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein.
Duquerroy S; Vigouroux A; Rottier PJ; Rey FA; Bosch BJ
Virology; 2005 May; 335(2):276-85. PubMed ID: 15840526
[TBL] [Abstract][Full Text] [Related]
24. Structural characterization of the SARS-coronavirus spike S fusion protein core.
Tripet B; Howard MW; Jobling M; Holmes RK; Holmes KV; Hodges RS
J Biol Chem; 2004 May; 279(20):20836-49. PubMed ID: 14996844
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide.
Madu IG; Roth SL; Belouzard S; Whittaker GR
J Virol; 2009 Aug; 83(15):7411-21. PubMed ID: 19439480
[TBL] [Abstract][Full Text] [Related]
26. Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization.
Chen J; Miao L; Li JM; Li YY; Zhu QY; Zhou CL; Fang HQ; Chen HP
World J Gastroenterol; 2005 Oct; 11(39):6159-64. PubMed ID: 16273643
[TBL] [Abstract][Full Text] [Related]
27. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
28. A convenient cell fusion assay for the study of SARS-CoV entry and inhibition.
Sha Y; Wu Y; Cao Z; Xu X; Wu W; Jiang D; Mao X; Liu H; Zhu Y; Gong R; Li W
IUBMB Life; 2006 Aug; 58(8):480-6. PubMed ID: 16916786
[TBL] [Abstract][Full Text] [Related]
29. Characterization of HCoV-229E fusion core: implications for structure basis of coronavirus membrane fusion.
Liu C; Feng Y; Gao F; Zhang Q; Wang M
Biochem Biophys Res Commun; 2006 Jul; 345(3):1108-15. PubMed ID: 16714001
[TBL] [Abstract][Full Text] [Related]
30. Serine-scanning mutagenesis studies of the C-terminal heptad repeats in the SARS coronavirus S glycoprotein highlight the important role of the short helical region.
Follis KE; York J; Nunberg JH
Virology; 2005 Oct; 341(1):122-9. PubMed ID: 16081124
[TBL] [Abstract][Full Text] [Related]
31. The SARS-CoV S glycoprotein.
Xiao X; Dimitrov DS
Cell Mol Life Sci; 2004 Oct; 61(19-20):2428-30. PubMed ID: 15526150
[TBL] [Abstract][Full Text] [Related]
32. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2.
Ling R; Dai Y; Huang B; Huang W; Yu J; Lu X; Jiang Y
Peptides; 2020 Aug; 130():170328. PubMed ID: 32380200
[TBL] [Abstract][Full Text] [Related]
33. Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.
Sun Y; Zhang H; Shi J; Zhang Z; Gong R
Viruses; 2017 Sep; 9(9):. PubMed ID: 28906430
[TBL] [Abstract][Full Text] [Related]
34. Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion.
Petit CM; Melancon JM; Chouljenko VN; Colgrove R; Farzan M; Knipe DM; Kousoulas KG
Virology; 2005 Oct; 341(2):215-30. PubMed ID: 16099010
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the prefusion and transition states of severe acute respiratory syndrome coronavirus S2-HR2.
McReynolds S; Jiang S; Guo Y; Celigoy J; Schar C; Rong L; Caffrey M
Biochemistry; 2008 Jul; 47(26):6802-8. PubMed ID: 18540634
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.
Sainz B; Mossel EC; Gallaher WR; Wimley WC; Peters CJ; Wilson RB; Garry RF
Virus Res; 2006 Sep; 120(1-2):146-55. PubMed ID: 16616792
[TBL] [Abstract][Full Text] [Related]
37. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus.
Zheng BJ; Guan Y; Hez ML; Sun H; Du L; Zheng Y; Wong KL; Chen H; Chen Y; Lu L; Tanner JA; Watt RM; Niccolai N; Bernini A; Spiga O; Woo PC; Kung HF; Yuen KY; Huang JD
Antivir Ther; 2005; 10(3):393-403. PubMed ID: 15918330
[TBL] [Abstract][Full Text] [Related]
38. Design and characterization of viral polypeptide inhibitors targeting Newcastle disease virus fusion.
Zhu J; Jiang X; Liu Y; Tien P; Gao GF
J Mol Biol; 2005 Dec; 354(3):601-13. PubMed ID: 16253271
[TBL] [Abstract][Full Text] [Related]
39. Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion.
Wang E; Sun X; Qian Y; Zhao L; Tien P; Gao GF
Biochem Biophys Res Commun; 2003 Mar; 302(3):469-75. PubMed ID: 12615056
[TBL] [Abstract][Full Text] [Related]
40. An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry.
Lin X; Guo L; Lin S; Chen Z; Yang F; Yang J; Wang L; Wen A; Duan Y; Zhang X; Dai Y; Yin K; Yuan X; Yu C; He B; Cao Y; Dong H; Li J; Zhao Q; Lu G
Emerg Microbes Infect; 2022 Dec; 11(1):1920-1935. PubMed ID: 35757908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
